Background: Amyloid-ß positivity (Aß+) based on PET imaging is part of the enrollment
criteria for many of the clinical trials of Alzheimer's disease (AD), particularly in trials for …

Background: Amyloid-ß (Aß) evaluation in amnestic mild cognitive impairment (aMCI)
patients is important for predicting conversion to Alzheimer's disease. However, Aß …

Amyloid-β (A β) is the target in many clinical trials for Alzheimer's disease (AD). Preclinical
AD patients are heterogeneous with regards to different backgrounds and diagnosis …

Background: Most clinical trials focus on amyloid-β positive (Aβ+) amnestic mild cognitive
impairment (aMCI), but screening failures are high because only a half of patients with aMCI …

Alzheimer's disease biomarkers are becoming increasingly important for characterizing the
longitudinal course of disease, predicting the timing of clinical and cognitive symptoms, and …

Abstract Introduction Clinical trials in Alzheimer's disease are aimed at early stages of
disease, including preclinical Alzheimer's disease. The high cost and time required to …

Abstract Background Plasma biomarkers for Alzheimer's disease (AD) have broad potential
as screening tools in primary care and disease-modifying trials. Detecting elevated amyloid …

Introduction To construct a prognostic model based on amyloid positron emission
tomography (PET) to predict clinical progression in individual patients with mild cognitive …

Assessment of disease biomarkers, particularly thein vivoassessment of amyloid-ß (Aß)
burden with positron emission tomography (PET), is gradually becoming central to the …

The importance of early interventions in Alzheimer's disease (AD) emphasizes the need to
accurately and efficiently identify at-risk individuals. Although many dementia prediction …